·　　·

B

ㄴ

【　】　　B

128　　B

64　　1 2 3 4

1　　3

P 0.05　　4　　*P* 0.01　　2

1 2 3　　4　　*P* 0.01　　3

3　　*P* 0.05　　4　　*P*

0.01　　B

【关　】

Application of compound B multi-fungal ointment hormone in elderly non-surgical wound healing in diabetic foot ulcers

Lyu Lei, Zhang Zhaoxin.Department of Burns, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China

Corresponding author: Zhang Zhaoxin, Email: sskzzx@163.com

Abstract　**Objective**　To investigate the compound polymyxin B ointment application operation repair in non senile diabetic foot ulcers. **Methods**　128 cases of elderly patients with diabetic foot wound using drugs according to different randomly divided into experimental group(compound compound nystatin group), and control group (silver sulfadiazine group), each group of 64 cases. In the expression of 1 weeks after treatment, 2 weeks, 3 weeks, 4 weeks were compared between the two groups of patients the wound tissue bacterial quantity, wound healing rate and the expression of epidermal growth factor. **Results**　(1) In 3 weeks after the start of treatment when the patients in experimental group wound tissue bacterial quantity mean less than that of the control group (*P*<0.05), after fourth weeks was significantly less than the control group(*P*<0.01); (2) Two groups of patients the wound healing rate in the treatment of 1, 2, 3 weeks had no obvious difference, was significantly higher than that in control group, the experimental group was after 4 weeks of healing(*P*<0.01); (3) 3 weeks after the treatment, two patients with epidermal growth factor was statistically significant(*P*<0.05), fourth weeks had significant difference (*P*<0.01). **Conclusions**　Compound nystatin B ointment applied to systemic infection has been controlled, but local infection is heavy, old base lesions, difficult to withstand repeated anesthesia operation after debridement and skin grafting wound closure in elderly patients. The compound multi nystatin ointment topical B is a safe, effective, easy to repair and treatment of diabetes foot ulcer.

Key words　Diabetic foot;　Aged;　Non operation

DOI:10.3877/cma.j.issn.1674-0785.2014.14.001

2012211A090

830001

Email: sskzzx@163.com

2011 9 240
[1]

4% 10%[2]

[3]

[4]

74%[5]

[6-12]

[13-14]

B

与

1.

2013 1 2014
1 128 78 50
60 83 14.61±3.58
10 20 15.52±10.33
5.7 8.6 mmol/L 6.66±1.19 mmol/L
One-Touch
20 160 d 122.3±34.50 d

1　　cfu/g　$\bar{x} \pm s$

		1	2	3	4
A	64	$(1.21\pm0.42)\times10^{9}$	$(7.05\pm1.29)\times10^{6}$	$(9.28\pm3.76)\times10^{4a}$	$(5.86\pm1.31)\times10^{3b}$
B	64	$(1.28\pm0.51)\times10^{9}$	$(7.54\pm1.34)\times10^{6}$	$(0.72\pm0.34)\times10^{6}$	$(3.27\pm4.12)\times10^{5}$

B　　^{a}P　0.05　^{b}P　0.01

P　0.05

50 μg

SDS-PAGE　　Fluors Mutilmager

Bio-Rad　　Quantity One 4.0

mean value intensity　MVI

EGF　　ASA

[17]ASA

SPSS 16.0　　0.1%　　0.7%　　3.5%

±　　$\bar{x} \pm s$　　18.3%　　93.3%

t　　P　0.05

7　10 d

1.　　128

128

214　　57　　2

214　　200　　14

115

85

MRSA

MRCNS　　MDR-AB

2.　　1　　3

A　　B　　P　0.05

4　　B　　P　0.01

3.　　2

1　2　3　　4　　A

B　　P　0.01

[18]

2

[19]

%　$\bar{x} \pm s$

		1	2	3	4
A	64	9.42±1.89	15.37±0.15	35.29±1.68	68.29±2.51
B	64	9.46±1.73	15.14±1.18	34.17±1.57	50.14±2.38[a]

A　　^{a}P　0.01

4. EGF　　1　　EGF

A　　B

3　　4　　A　EGF　　B



EGF -2 FGF-2
-AB PDGF-AB

3 A EGF B
B

参

[1] Yang SH, Dou KF, Song WJ. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(25): 2425-2426; author reply 2426.
[2] , , , .
[J]. , 2012, 92(24): 1686-1689.
[3] , . [J].
, 2012, 32(6): 1153-1156.
[4] , , . ( )32 l [J].
, 2008, 21(7): 546-547.
[5] Robbins JM, Strauss G, Aron D, et al. Mortality rates and diabetic foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration?[J]. J Am Podiatr Med Assoc, 2008, 98(6): 489-493.
[6] .
[J]. , 2009, 25: 681-682.
[7] .
[J]. , 2009, 25: 589-590.
[8] ,pl436 (.)Tj/C2_0 1l Tf0 Tc 0 Tw 0.492 0 <055F0CD13F55>2AA12132B992B9917FE3CCA112C>7470CB432F407590F55>D6415AB>]TJ/TT0 1 Tf-5.012 Tc 5.0
Θ